NEW YORK, Feb. 21, 2023 /PRNewswire/ -- Caligan Partners LP ("Caligan"), one of the largest shareholders of Anika Therapeutics, Inc. (NASDAQ: ANIK) ("Anika" or the "Company"), today issued an open letter to the board of directors of Anika in connection with Anika's poor share performance, caused by the heavy losses it is incurring in its joint preservation segment, and its failure to maximize the value of Anika's viscosupplement portfolio.
The full text of the letter is in the attached PDF.
About Caligan Partners LP
Caligan Partners LP ("Caligan") is an SEC-registered investment advisor focused on active engagement with small and midcap companies within life sciences.
| Last Trade: | US$9.38 |
| Daily Change: | 0.15 1.63 |
| Daily Volume: | 160,334 |
| Market Cap: | US$135.260M |
February 25, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
